CPAP vs Oral Appliance: Which Sleep Apnea Treatment Is Right for You?

What Is CPAP and How Well Does It Work?

CPAP (continuous positive airway pressure) delivers a constant stream of pressurized air through a mask to splint the upper airway open during sleep. For moderate-to-severe obstructive sleep apnea, defined as an apnea-hypopnea index (AHI) above 15 events per hour, CPAP is the treatment most sleep societies recommend first. The 2019 American Academy of Sleep Medicine (AASM) clinical practice guideline states that "CPAP is recommended for all adults with OSA" and specifies that the strength of recommendation is strong for AHI >15 [1].

Multiple randomized trials confirm the AHI-lowering effect. The SAVE trial (N=2,717) enrolled patients with moderate-to-severe OSA and established cardiovascular disease. CPAP reduced AHI from a median of 29.0 to 3.7 events per hour, a 87% reduction, though the trial did not demonstrate a reduction in the composite cardiovascular outcome at 3.7 years [2]. That finding surprised many clinicians, and it shifted the field's narrative from "CPAP cures heart disease" to "CPAP controls airway obstruction and improves sleepiness, but cardiovascular benefit may require much longer treatment or specific subpopulations."

Excessive daytime sleepiness, measured by the Epworth Sleepiness Scale (ESS), drops by roughly 2.5 points on CPAP in meta-analyses of randomized trials [3]. Blood pressure falls by a modest but statistically significant 2 to 3 mmHg systolic in patients who are non-sleepy [4].

The persistent problem with CPAP is adherence. Objective download data show that roughly 46 to 83% of patients use CPAP on any given night, and average nightly use often falls below the commonly cited 4-hour threshold [5]. Mask leak, pressure intolerance, claustrophobia, and partner disturbance are the most frequent complaints.

How Oral Appliances Compare to CPAP

Oral appliances, specifically mandibular advancement devices (MADs), reposition the lower jaw and tongue forward to increase retroglossal airway space during sleep. They are custom-fabricated by a dental sleep medicine specialist and titrated over 6, 12 clinic visits.

Head-to-head randomized data show CPAP reduces AHI more than MADs, but MADs produce comparable improvements in sleepiness and quality of life because patients wear them more consistently. A Cochrane systematic review of 67 trials concluded that CPAP was superior to oral appliances for reducing AHI (weighted mean difference: 7.97 events/hour favoring CPAP) yet the two treatments produced similar Epworth scores at follow-up, likely because of the adherence gap [6]. The AASM/AADSM joint guideline from 2015 (reaffirmed 2019) recommends oral appliances as an alternative to CPAP "for patients who prefer it, or who are unable to tolerate CPAP therapy" [7].

MAD candidates with the best outcomes tend to have:

• AHI between 5 and 30 events per hour
• Body mass index (BMI) <35 kg/m²
• Significant supine-dependent or REM-dependent OSA
• Adequate dentition (at least 8, 10 anchor teeth)

Side effects of MADs include temporomandibular joint discomfort (reported in up to 31% of users in the first month), tooth soreness, and small but measurable changes in occlusion after 2 or more years of nightly use [8]. Annual dental follow-up is recommended to monitor bite changes.

Combining CPAP and Oral Appliance: When Dual Therapy Applies

Some patients with severe OSA achieve adequate AHI control only by combining a MAD with auto-titrating CPAP at lower pressure settings, a combination that reduces mask leak and improves comfort. A small but well-designed crossover trial published in SLEEP (N=20) found that combination therapy lowered the required therapeutic CPAP pressure by a mean of 3.4 cmH₂O compared with CPAP alone, while maintaining AHI <5 events per hour in 90% of participants [9]. Combination therapy adds cost and complexity, but for the subgroup with CPAP pressure intolerance who cannot switch to oral appliance monotherapy, it is a practical middle path.

Positional Therapy and Surgical Alternatives

Not every patient falls into a CPAP-vs-MAD binary. Positional OSA, defined as AHI at least twice as high in the supine position as non-supine, accounts for roughly 56% of OSA cases in some cohorts [10]. Positional therapy devices that prevent supine sleeping (vibrotactile trainers, positional pillows) reduce AHI by approximately 47 to 53% in positional OSA. The NightBalance Lunoa device received FDA clearance in 2014 and showed in a 90-patient randomized trial that it reduced AHI from 18.2 to 8.6 events per hour at 90 days [11].

Surgical options include uvulopalatopharyngoplasty (UPPP), hypoglossal nerve stimulation (HNS, e.g., Inspire), and maxillomandibular advancement (MMA). Inspire therapy is the most evidence-backed surgical option for CPAP-intolerant patients; the STAR trial (N=126) reported a 68% reduction in AHI and 70% reduction in oxygen desaturation index at 12 months [12].

Insomnia and OSA: Why Co-Treatment Matters

About 39 to 58% of OSA patients report clinically significant insomnia symptoms [13]. Treating only the obstructive component without addressing the hyperarousal of insomnia leads to CPAP non-adherence. The AASM 2021 clinical practice guideline on chronic insomnia disorder identifies cognitive behavioral therapy for insomnia (CBT-I) as the first-line treatment, ahead of all pharmacotherapy [14].

When pharmacotherapy is added, drug selection should account for whether apnea is controlled and whether respiratory depression risk matters.

Zolpidem (Ambien) vs Eszopiclone (Lunesta): Z-Drug Comparison

Zolpidem (Ambien, Edluar, Zolpimist) and eszopiclone (Lunesta) are both non-benzodiazepine GABA-A positive allosteric modulators, commonly called Z-drugs. Both are Schedule IV controlled substances under the Controlled Substances Act [15].

Zolpidem immediate-release (5 to 10 mg) has a half-life of approximately 2.5 hours and targets sleep-onset latency. The extended-release formulation (Ambien CR, 6.25 to 12.5 mg) also addresses sleep maintenance. The FDA reduced recommended starting doses in 2013 after pharmacokinetic data showed that women metabolize zolpidem 45% more slowly than men, leaving residual blood levels above the 50 ng/mL impairment threshold in 15% of women 8 hours after a 10 mg dose [16].

Eszopiclone has a longer half-life of 6 hours and was the first sleep drug approved by the FDA without a duration-of-use restriction. A 6-month randomized trial (N=788) showed eszopiclone 3 mg reduced sleep-onset latency by 15 minutes and wake-after-sleep-onset by 25 minutes compared with placebo, with no evidence of tolerance through week 24 [17]. Next-morning residual sedation is more frequent with eszopiclone than with zolpidem IR, particularly at the 3 mg dose.

Neither Z-drug is preferred over the other by current AASM guidelines; the choice comes down to whether onset difficulty (favoring zolpidem IR) or sleep maintenance difficulty (favoring eszopiclone or zolpidem ER) dominates the patient's complaint [14].

Trazodone vs Mirtazapine for Insomnia

Trazodone and mirtazapine are antidepressants used at sub-antidepressant doses to treat insomnia. Neither is FDA-approved specifically for insomnia, so both are prescribed off-label in this context [18].

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI). At doses of 50 to 150 mg taken 30 to 60 minutes before bed, it increases slow-wave sleep and reduces sleep-onset latency. A double-blind crossover trial (N=15) showed trazodone 50 mg increased total sleep time by 44 minutes vs placebo (P<0.05) in primary insomnia without significant next-morning sedation at this dose range [19]. At doses above 150 mg, morning grogginess becomes more common. Trazodone carries a small risk of priapism (estimated 1 in 6,000 male patients) and orthostatic hypotension, making it less suitable for elderly fallers [20].

Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA). Its sedating effects are paradoxically greatest at lower doses (7.5 to 15 mg) because of potent H1 histamine blockade that diminishes relative to noradrenergic effects at higher doses. In a small controlled trial (N=24), mirtazapine 15 mg increased total sleep time by 58 minutes and reduced wake-after-sleep-onset by 35 minutes [21]. Weight gain averaging 1.5 to 2.5 kg over 6 weeks is the most clinically relevant side effect, particularly for patients already managing obesity or metabolic syndrome.

Neither drug causes the next-day driving impairment associated with high-dose Z-drugs, but both can worsen restless legs syndrome, which clinicians should screen for before prescribing.

DORAs: Suvorexant (Belsomra) vs Lemborexant (Dayvigo) vs Z-Drugs

Dual orexin receptor antagonists (DORAs) represent a mechanistically distinct class. Instead of sedating the brain globally, suvorexant (Belsomra, 10 to 20 mg) and lemborexant (Dayvigo, 5 to 10 mg) block orexin-1 and orexin-2 receptors to suppress the wake-promoting signal [22].

The SUNRISE-1 and SUNRISE-2 trials (combined N=approximately 1,900) established lemborexant's efficacy for both sleep-onset and sleep-maintenance insomnia. In SUNRISE-2 (N=900, 12-month duration), lemborexant 5 mg and 10 mg reduced subjective sleep-onset latency and improved sleep efficiency compared with placebo with no evidence of tolerance, rebound insomnia, or next-morning residual sedation above the pre-specified threshold [23].

Compared with Z-drugs, DORAs produce less respiratory depression, making them the preferred pharmacologic option for patients with controlled OSA on CPAP who also have insomnia. The FDA prescribing information for suvorexant notes it should be used with caution in patients with compromised respiratory function, but does not carry the same respiratory-depression black-box warning as benzodiazepines [24]. A dedicated polysomnography study found suvorexant 40 mg (twice the maximum approved dose) did not worsen AHI in patients with mild-to-moderate OSA [25].

The main DORA disadvantage is cost. Suvorexant and lemborexant remain brand-only as of 2025, with cash prices of $350, $420 per 30-day supply, versus generic zolpidem at under $15.

The HealthRX clinical decision framework for sleep pharmacotherapy:

Step 1. Rule out untreated OSA (screen with STOP-BANG; refer for polysomnography if score >3). Step 2. Start CBT-I (digital or therapist-delivered) as the anchor treatment for insomnia regardless of pharmacotherapy plan. Step 3. Select pharmacotherapy by dominant complaint and risk profile:

• Sleep-onset only, no abuse risk: ramelteon 8 mg or low-dose doxepin 3 mg
• Sleep-onset, low abuse risk, no respiratory concern: zolpidem IR 5 mg (women) / 10 mg (men)
• Sleep-maintenance dominant: eszopiclone 2 to 3 mg or DORA (suvorexant 10 to 20 mg)
• Depression plus insomnia: mirtazapine 7.5 to 15 mg or trazodone 50 to 100 mg
• Controlled OSA on CPAP with insomnia: DORA preferred over Z-drug
• Circadian-phase delay or shift work: melatonin 0.5 to 3 mg timed 5 to 6 hours before target sleep, or ramelteon 8 mg

Melatonin vs Ramelteon: OTC vs Prescription Circadian Agents

Melatonin supplements are not FDA-regulated as drugs. A 2023 analysis of 31 commercial melatonin products found that actual melatonin content varied from 74% to 347% of the labeled dose, with 26% of products also containing serotonin not listed on the label [26]. Effective circadian-shifting doses in research are low: 0.5 mg taken 5 to 6 hours before intended sleep onset shifts the dim-light melatonin onset (DLMO) by approximately 1.0 to 1.5 hours in adults with delayed sleep-wake phase disorder [27].

Ramelteon (Rozerem, 8 mg) is a prescription melatonin receptor agonist with high selectivity for MT1 and MT2 receptors. Its binding affinity for MT1/MT2 is approximately 3, 16 times greater than exogenous melatonin [28]. A randomized trial (N=405) demonstrated that ramelteon 8 mg reduced latency to persistent sleep by 13.7 minutes versus placebo in adults with chronic insomnia, with effect maintained at 5 weeks [29]. Unlike zolpidem, ramelteon is not a controlled substance. The FDA's 2005 approval label explicitly confirms no evidence of abuse, dependence, or withdrawal in clinical trials [30].

For jet lag specifically, 0.5 to 5 mg fast-release melatonin taken at local bedtime on arrival reduces jet-lag symptoms in eastward travel by approximately 50%, according to a Cochrane review of 10 trials [31]. Ramelteon is not well-studied for jet lag and does not have an indication for it.

The practical difference is reliability of dose. Ramelteon delivers a precise 8 mg in a pharmaceutical-grade tablet every time. OTC melatonin may deliver anywhere from 0.5 mg to 12.4 mg per gummy depending on brand, batch, and product format.

Pediatric and Geriatric Considerations

In adults over 65, the Beers Criteria (2023 update) lists benzodiazepines and Z-drugs as potentially inappropriate due to increased fall risk, fracture risk, and cognitive impairment [32]. The FDA's 2019 boxed warning extended to all Z-drugs, cautioning against use in patients with histories of parasomnias [33]. DORAs and low-dose doxepin (3 to 6 mg, Silenor) have more favorable profiles for older adults.

In children with autism spectrum disorder and neurodevelopmental conditions, melatonin is the most studied pharmacologic sleep aid. A randomized trial (N=146) found prolonged-release melatonin (Slenyto, 2 to 10 mg) reduced sleep-onset latency by 37.5 minutes vs placebo at 13 weeks (P<0.001) [34].

Monitoring and Titration: Practical Numbers

CPAP adherence downloads should be reviewed at the first follow-up visit 30 days after initiation. The CMS Medicare coverage standard requires >4 hours of use on >70% of nights during a 30-day period within the first 90 days to maintain equipment coverage [35]. Residual AHI on CPAP should be <5 events per hour; residual AHI 5, 10 may indicate mouth leak, suboptimal pressure, or positional issues.

MAD titration typically advances the mandible in 0.25 mm increments every 1 to 2 weeks. Most patients reach therapeutic position within 8 to 12 mm of maximum protrusion. A follow-up polysomnography or home sleep apnea test should be performed after final titration to confirm AHI <5 events per hour [7].

For Z-drugs, the minimum effective dose should always be used. The FDA recommends 5 mg (women) or 5 to 10 mg (men) for zolpidem IR, and 1 mg for eszopiclone as a starting dose in elderly patients [16]. Prescribers should reassess the need for continued pharmacotherapy at 4-week intervals and attempt a supervised taper after 4 to 8 weeks of use.